In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's ...

Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong ...

Teva Pharmaceutical (TEVA) stock surges as the company posts better than expected Q3 2025 results and raises the midpoint of ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

Teva Pharmaceutical CEO Richard Francis speaks about 3Q earnings on Bloomberg BusinessWeek with Bloomberg's Katie Greifeld ...

Toast Inc (NYSE: TOST) gained 9.3% to $39.00 after the company reported better-than-expected quarterly financial results. Also, Morgan Stanley maintained an Overweight rating on the stock and raised ...

For an accessible version of this Press Release, please visit reports revenues of $4.5 billion in the third quarter of ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...